KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells
Disease and Therapeutics
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Citation
KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. // Disease and Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S305099982600023X?dgcid=rss_sd_all
KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. Disease and Therapeutics. https://www.sciencedirect.com/science/article/pii/S305099982600023X?dgcid=rss_sd_all
“KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells.” Disease and Therapeutics.
@article{article43301,
title = {KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells},
journal = {Disease and Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S305099982600023X?dgcid=rss_sd_all}
}